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Type I interferonHost cells respond to viral infection by the production of type I interferons (IFNs), which induce the
expression of antiviral genes. Herpes simplex virus I (HSV-1) encodes many mechanisms that inhibit the
type I IFN response, including the ICP27-dependent inhibition of type I IFN signaling. Here we show
inhibition of Stat-1 nuclear accumulation in cells that express ICP27. ICP27 expression also induces the
secretion of a small, heat-stable type I IFN antagonizing protein that inhibits Stat-1 nuclear accumulation. We
show that the inhibition of IFN-induced Stat-1 phosphorylation occurs at or upstream of Jak-1
phosphorylation. Finally, we show that ISG15 expression is induced after IFNα treatment in mock-infected
cells, but not cells infected with WT HSV-1 or ICP27− HSV-1. These data suggest that HSV-1 has evolved
multiple mechanisms to inhibit IFN signaling not only in infected cells, but also in neighboring cells, thereby
allowing for increased viral replication and spread.
© 2009 Elsevier Inc. All rights reserved.Introduction
One of the ﬁrst lines of defense that is activated upon infection of a
hostwith a pathogen is the interferon (IFN) response. Type I IFNs (α,β,
ω, τ) are a family of antiviral cytokines induced in most cell types by
viral infection or the presence of double-stranded RNA and acts in an
autocrine and paracrine manner to establish an antiviral state in host
cells (Sato et al., 2000). Type II IFN (γ) is a pro-inﬂammatory cytokine
induced in activated T cells and natural killer cells (Schiller et al.,
2006). Though there are distinct similarities in the signaling pathways
activated by each type of IFN, there are also some key differences. Each
family of IFN binds to a distinct heterodimeric receptor (Kotenko et al.,
2003; Platanias and Colamonici, 1992; Platanias, Uddin, and Colamo-
nici, 1994; Sheppard and York, 1990), which causes the activation of
Janus kinases (Jaks) by phosphorylation. The kinases Jak-1 and Tyk-2
are activated in the case of type I IFN, and Jak-1 and Jak-2 for type II IFN
(Darnell, Kerr, and Stark, 1994; David et al., 1993; Platanias, Uddin, and
Colamonici, 1994). The Jaks phosphorylate signal transducers and
activators of transcription (Stats)-1 and-2, in type I IFN signaling, and
only Stat-1 after exposure to IFNγ (Platanias, Uddin, and Colamonici,
1994; Schindler et al., 1992; Uddin, Chamdin, and Platanias, 1995).
Once activated by phosphorylation, Stat-1 either homodimerizes
(IFNγ) or forms a complex with Stat-2 and with interferon regulatory
factor 9 (IFNα/β) (Bandyopadhyay et al., 1995; Kessler et al., 1990;
Ramana et al., 2002). These complexes translocate into the nucleus and
bind speciﬁc DNA elements, interferon stimulated response elements. Knipe).
ll rights reserved.(ISREs, type I signaling) or gamma activated sequences (GASs, type II
signaling), to activate transcription of interferon stimulated genes
(ISGs). ISGs contribute to the pro-inﬂammatory or antiviral state and
include RNase L, which degrades viral and cellular RNAs (Dong and
Silverman, 1995; Kerr and Brown, 1978) and PKR, which inhibits
protein synthesis by phosphorylating the translation initiation factor
eIF2a (Der et al., 1998; Samuel, 1979a,b).
Viruses have evolved mechanisms to evade or counteract the
effects of IFNα/β signaling. Several viral proteins, such as the
inﬂuenza virus NS1 protein and the human papilloma virus (HPV)
E6 oncoprotein inhibit expression of type I IFN by blocking the
activation or activity of interferon regulatory factor 3 (IRF3), a
transcription factor important for type I IFN production (Ronco et al.,
1998; Talon et al., 2000). The vaccinia virus protein B18R is secreted
from cells and binds IFN in the extracellular space to prevent its
binding to cells (Alcamí and Smith, 1995; Colamonici et al., 1995).
Other viral proteins, such as cytomegalovirus (CMV) IE1, measles V
protein, and dengue virus NS4B, inhibit the signaling pathway itself
(Gao et al., 1997; Muñoz-Jordan et al., 2003; Paulus, Krauss, and
Nevels, 2006; Yokota et al., 2003).
Herpes simplex virus 1 (HSV-1) is a large, double-stranded DNA
virus that productively infects epithelial cells and establishes a latent
infection in sensory ganglia for the life of the host (Roizman, Knipe,
and Whitley, 2007). In cells that have been exposed to IFNα prior to
infection, HSV-1 replication is severely reduced compared with cells
infected in the absence of IFN (Altinkilic and Brandner, 1988;
Mittnacht et al., 1988; Oberman and Panet, 1988; Pierce et al.,
2005). However, cells that are infected with HSV-1 and then treated
with IFN show reduced IFN signaling and decreased ISRE reporter
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2008; Yokota et al., 2001). One anti-IFN activity that has been
characterized for HSV-1 is the ICP0-dependent inhibition of IRF-3
stimulated IFNβ expression (Melroe et al., 2007). Second, the HSV-1
late protein γ34.5 binds protein phosphatase 1 to counteract the
activity of PKR, by causing the dephosphorylation and reactivation of
eIF2a (Chou et al., 1995; He, Gross, and Roizman, 1997, 1998; Leib et
al., 2000). We have also shown that HSV-1 ICP27 is necessary and
sufﬁcient to inhibit IFNα-induced Stat-1 phosphorylation and nuclear
accumulation (Johnson, Song, and Knipe, 2008). The effect was
observed by 2–4 hpi, so this is likely an early event in HSV infection.
ICP27 is a multifunctional immediate early protein with homologs
in all herpesviruses (Roizman, Knipe, and Whitley, 2007) that is
essential for transcription of some early and late viral proteins (Jean et
al., 2001). Early in infection it is mostly nuclear but has been shown
to shuttle between the nucleus and cytoplasm later in infection
(Clements et al., 2004; Soliman, Sandri-Goldin, and Silverstein, 1997).
It has roles in transcriptional regulation through association with RNA
polymerase II (Zhou and Knipe, 2002) and translation through
association with translation factors eIF3, eIF4g, and PABP (Ellison et
al., 2005; Fontaine-Rodriguez and Knipe, 2008; Fontaine-Rodriguez et
al., 2004). ICP27 also affects RNA processing through interactions with
splicing machinery (Hardwicke and Sandri-Goldin, 1994; Hardy and
Sandri-Goldin, 1994; Phelan et al., 1993; Sandri-Goldin and Hibbard,
1996) and regulation of differential polyadenylation (Hann et al.,
1998; McGregor et al., 1996; McLauchlan et al., 1992; McLauchlan,
Simpson, and Clements, 1989). ICP27 associates with RNA via its RGG
box and CR1 regions to stabilize A/U-rich RNAs (Brown et al., 1995;
Ingram et al., 1996). In some studies, it has also been implicated in
nuclear export of some viral transcripts (Koffa et al., 2001; Mears and
Rice, 1998; Pearson, Knipe, and Coen, 2004; Sandri-Goldin, 1998;
Wadd et al., 1999). However, other groups have not seen a difference
in RNA export during infection with ICP27 mutant viruses (Ellison et
al., 2005; Fontaine-Rodriguez and Knipe, 2008; Pearson, Knipe, and
Coen, 2004).
We performed immunoﬂuorescence experiments to determine
that ICP27 was necessary and sufﬁcient for inhibition of Stat-1
phosphorylation and nuclear accumulation. In these experiments we
also observed that even after IFNα-treatment, many cells that did not
stain positive for ICP27 still did not show nuclear accumulation of
Stat-1 (Johnson, Song, and Knipe, 2008). It appeared that ICP27Fig. 1. HSV-1 infection inhibits IFN-induced nuclear accumulation of Stat-1 in surrounding
treated with IFN for 30 min before ﬁxation, as indicated. Immunoﬂuorescence was done
predominantly nuclear (A: white arrow), predominantly cytoplasmic (A: black arrow), or bo
that stained positive for ICP27 (B). Data shown are from cell counts from replicate cover slips
is representative of multiple experiments.expression was causing a bystander effect in surrounding cells
through an unknown mechanism.
There have been several hypotheses about the mechanism(s) by
which IFN signaling is inhibited by HSV-1, with possible mechanisms
being the HSV-1 virion host shut-off protein (vhs) or the cellular
suppressor of cytokine signaling protein SOCS-3 (Chee and Roizman,
2004; Yokota et al., 2005; Yokota et al., 2004). However, the actual
mechanism of inhibition is still unknown. In this study, we show that
HSV-1 infection inhibits IFN signaling at or before the phosphoryla-
tion of Jak-1. In exploring the bystander effect of ICP27 on
surrounding cells further, we have also found that HSV-1 infection
and ICP27 transfection cause the secretion of a heat-stable, protease-
sensitive soluble factor that inhibits IFNα-induced Stat-1 nuclear
accumulation in trans.
Results
HSV-1 infection causes bystander cell inhibition of IFNα-induced Stat-1
nuclear accumulation
In our previous study, we observed that a number of cells that
did not stain for ICP27 showed mostly cytoplasmic distribution of
Stat-1 even after treatment with IFNα (Johnson, Song, and Knipe,
2008). To examine the relationship between ICP27 and Stat-1
distribution in HSV-1 infected cells, we mock-infected or infected
Vero cells with WT HSV-1 for 10 h and treated with IFNα at 104 U/
mL for 30 min prior to ﬁxation. Cells were stained with antibodies to
Stat-1 and ICP27 and 200–250 cells per cover slip were scored
blindly for Stat-1 localization, as being nuclear, cytoplasmic, or both
(Fig. 1A, black arrow–cytoplasmic, white arrow–nuclear, white
arrow head–both).
In the absence of IFN, Stat-1 was mostly cytoplasmic in over 70%
and both nuclear and cytoplasmic in over 25% of mock-infected cells,
but after IFN treatment Stat-1 was redistributed to be approximately
75% nuclear and about 25% cytoplasmic and nuclear (Fig. 1B). After
HSV-1 infection, when roughly 20% of cells appeared to be infected (as
detected by ICP27 immunoﬂuorescence), Stat-1 was cytoplasmic in
nearly 70% of cells and both cytoplasmic and nuclear in about 30% of
cells in the absence of IFN (Fig. 1B). After IFNα treatment however,
Stat-1 accumulated in the nucleus of only approximately 45% of cells,
which is signiﬁcantly lower than in mock-infected cells (pb0.01).cells. Vero cells were mock infected or infected (MOI=3) with WT HSV-1 for 10 h and
with antibodies towards Stat-1 and ICP27. Stat-1 localization was scored as being
th (A: white arrow head). The percent of cells infected was determined by counting cells
, and statistical analysis was performed with the Student's t-test. The experiment shown
Fig. 2. ICP27 expression is sufﬁcient to inhibit IFN-induced Stat-1 nuclear accumulation
in surrounding cells. Vero cells were transfected with empty vector (pCI) or an ICP27
expression vector (pCI-ICP27) and treated with IFN for 30 min before ﬁxation.
Immunoﬂuorescence was done with antibodies speciﬁc for ICP27 and Stat-1 and Stat-1
localization was scored as in Fig. 1.
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signaling in more cells than those expressing detectable ICP27,
suggesting that IFN signaling was also inhibited in cells neighboring
the infected cells.
ICP27 is sufﬁcient for bystander cell inhibition of IFNα-induced Stat-1
nuclear accumulation
We showed previously that ICP27 is necessary and sufﬁcient to
inhibit IFNα-induced Stat-1 nuclear accumulation. To test whether
ICP27 was sufﬁcient to cause the bystander cell inhibition of Stat-1
nuclear accumulation, we transfected cells with empty vector or
ICP27 expression plasmid. At 24 h post-transfection, we treated cells
with IFNα at 104 U/mL for 30 min before ﬁxation. Cells were stained
for Stat-1 and ICP27 (for transfection efﬁciency), and 200–250 cells
per coverslip were scored for Stat-1 localization.Table 1
ICP27 causes the secretion of a heat-stable protease-sensitive IFN antagonist that is 10–50
Medium
from cells
transfected
with
Treatment IF
Empty vector None −
+
ICP27 vector −
+
Empty vector 55 °C 1 h, 95 °C 10 min −
+
ICP27 vector −
+
Empty vector 55 °C 1 h, 95 °C 10 min with proteinase K −
+
ICP27 vector −
+
Empty vector Filtered through 50 kDa pores −
+
ICP27 vector −
+
Empty vector Filtered through 10 kDa pores −
+
ICP27 vector −
+
⁎ Vero cells were transfected with empty vector (pCI) or an ICP27 expression vector (pC
untreated, heated to 55 °C for 60min and to 95 °C for 10min in the absence or presence of pro
cells. At 24 h after media transfer, these cells were treated with IFNα at 104 U/mL for 30 m
determined as in Fig. 1.
+ Compared with control medium from cells transfected with empty vector.Consistent with previous results, cells that were transfected with
empty vector showed predominantly cytoplasmic staining for Stat-1
(90% of cells, Fig. 2). After treatment with IFNα, over 85% of empty
vector-transfected cells showed Stat-1 accumulation in the nucleus
(Fig. 2). Cells that were transfected with an ICP27 expression vector
plasmid showed an evenmore dramatic effect than cells infected with
WT HSV-1, with nearly 100% cytoplasmic Stat-1 localization in the
absence of IFN and only approximately 1% of cells with nuclear
staining after IFN treatment (pb0.001, Fig. 2). About 15% of cells
stained positive for ICP27 (data not shown). These data suggested that
ICP27 expression is sufﬁcient to affect the type I IFN signaling in
surrounding cells, although it was possible that the other cells
expressed ICP27 at levels below the detection threshold of our
antibody.
ICP27 causes the release of a heat-stable, protease sensitive,
IFN-antagonizing factor
Some large DNA viruses encode proteins that are secreted from
cells and compete for binding with IFN and IFNAR (Alcamí and
Smith, 1995; Colamonici et al., 1995). To determine if the inhibition
of Stat-1 nuclear accumulation that we observed was the result of a
factor secreted by ICP27-expressing cells, we harvested medium
from cells transfected with an empty vector or pCI-ICP27,
transferred the medium to new cells and then treated the cells
with IFNα, and scored for Stat-1 localization as above. We observed
that cells incubated in medium from cells transfected with pCI
plasmid had predominantly cytoplasmic Stat-1 in the absence of
IFNα (69%, Table 1), and that after IFNα treatment, Stat-1
accumulated in the nucleus in most cells (81%, Table 1). Cells
grown in medium from cells transfected with the ICP27 plasmid
also showed predominantly cytoplasmic Stat-1 in the absence of IFN
(81%, Table 1), but the IFN-induced accumulation of Stat-1 in the
nucleus occurred in a signiﬁcantly smaller percentage of cells (37%)
than in cells grown in medium from pCI-transfected cells (pb0.05,
Table 1). Therefore, ICP27 expression caused the secretion of a
soluble IFN-antagonizing factor.kDa.
N % cells with StatI localization in⁎
Nucleus Cytoplasm Both
7±1
81±5
69±6
3±2
24±5
16±4
1±1
37±19, pb0.05+
81±2
40±15
18±3
21±4
0.5±0.5
75±4
68±4
1±1
32±3
24±2
2±2
41±3, pb0.01+
75±6
18±3
21±5
41±0.5
0.5±0.5
58±7
82±2
9±0.5
18±2
32±7
0.5±0.5
72±1, pN0.05
79±1
2±0.5
20±1
26±1
1±0.5
84±2
70±4
0.5±0.5
29±5
16±2
2±1
59±3, pb0.05+
69±3
2±0.5
28±3
39±3
3±1
74±14
70±3
4±5
31±2
22±6
3±1
77±4, pN0.25
67±2
2±0.5
31±3
20±4
I-ICP27). At 24 h post-transfection, medium from each culture was harvested and left
teinase K, or passed through a 50- or 10-kDa ﬁlter before being transferred to naïve Vero
in, as indicated, ﬁxed, and stained for Stat-1. The distribution of Stat-1 localization was
Fig. 3. Type I, but not type II, IFN-induced Stat-1 phosphorylation is inhibited by HSV-1.
Vero cells were mock infected (lanes 1–3) or infected (MOI=20) withWT HSV-1 (KOS,
lanes 4–6) and treated with IFN (lanes 2, 5) or IFN (lanes 3, 6) for 30min before harvest.
Western blot analysis was done with antibodies to pStat-1, Stat-1, ICP27, and actin.
Fig. 4. HSV-1 inhibits IFN-induced ISG15 expression in an ICP27-independent manner.
Vero cells were mock infected (lanes 1–2) or infected (MOI=20) with wt HSV-1 (KOS,
lanes 3–4), or ICP27− virus (5dl1.2, lanes 5–6) and treated with IFN (even lanes) for 2 h
before harvest. Western blot analysis was done with antibodies speciﬁc for pStat-1,
ISG15, and GAPDH.
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heat stability. Vero cells were transfected with empty vector or ICP27
expression vector. At 24 h post-transfection, we harvested the
medium from the transfected cells and incubated it at 55 °C for
60 min, at 95 °C for 10 min, cooled it to 37 °C, and transferred the
medium to newVero cells. These cells were then treatedwith IFNα for
30 min, ﬁxed, stained with antibodies to Stat-1, and scored for Stat-1
localization as above.
Consistent with previous results, cells incubated in medium from
empty vector-or ICP27 expression plasmid-transfected cells showed
mostly cytoplasmic Stat-1 localization in the absence of IFN (68% and
75%, respectively, Table 1). However, after IFNα treatment, Stat-1 was
nuclear in 75% of cells grown in medium from empty vector-
transfected cells, but in only 41% of cells grown in medium from
ICP27 plasmid-transfected cells (Table 1), signiﬁcantly different
(pb0.01) from cells treated with control medium.
To further determine the molecular nature of the secreted factor,
we incubated the media with proteinase K, and transferred them to
new Vero cells, which were treated with IFNα as indicated (Table 1)
for 30 min, ﬁxed, stained, and scored for Stat-1 localization. Cells
grown in proteinase K-treated medium from cells transfected with
empty vector or ICP27 expression vector showed mostly cytoplasmic
Stat-1 localization in the absence of IFN treatment (82% and 79% of
cells, respectively, Table 1). Cells grown in proteinase K-treated
medium had mostly nuclear localization after IFNα treatment,
regardless of whether the source of the medium was cells transfected
with empty vector or ICP27 expression vector (58% and 72%,
respectively, Table 1).
To determine the approximate size of the factor released from cells
that express ICP27, we transfected cells with empty vector or ICP27
expression plasmid, harvested the medium as above, and passed it
through molecular sizing ﬁlters with 10 or 50 kDa molecular weight
thresholds before overlaying naïve Vero cells. Cells were treated with
IFNα, stained, and scored for Stat-1 localization as above.
In the absence of IFN, cells that were grown in medium from cells
transfected with either plasmid ﬁltered through the 50-kDa ﬁlter
showed mostly cytoplasmic Stat-1 localization (70%, Table 1). After
IFN treatment, there was a shift tomostly nuclear Stat-1 in cells grown
in medium from pCI-transfected cells (84%, Table 1), which was
signiﬁcantly decreased in cells grown in medium from pCI-ICP27-
transfected cells (59%, pb0.005, Table 1). Cells grown in medium
passed through the 10-kDa ﬁlter showed mostly cytoplasmic Stat-1
localization in the absence of IFN (70% for medium from pCI-
transfected cells, 67% for medium from pCI-ICP27-transfected cells,
Table 1). After IFN treatment, Stat-1 accumulated in the nucleus of
most cells grown in medium from pCI-transfected cells (74%, Table 1)and cells grown in medium from pCI-ICP27-transfected cells (77%,
Table 1).
In total, these results argued that the IFN-antagonizing factor
secreted from ICP27-expressing cells was a heat-stable, protease
sensitive protein between 10 and 50 kDa in molecular weight.
Stage of IFN signaling pathway affected by HSV
Type I, but not type II, IFN-induced Stat-1 phosphorylation is inhibited by
HSV-1 infection
We have shown that ICP27 expression causes the secretion of a
soluble protein that inhibits IFNα-induced Stat-1 nuclear localization.
However, the stage of the signaling pathway affected was still
unknown. Jak-1 and Stat-1 are shared factors between the type I
and type II IFN signaling pathways (Samuel, 2001). Type II IFN
signaling has been shown to be affected by HSV-1, as detected by
reporter gene assay, albeit at signiﬁcantly reduced levels compared
with the inhibition of type I IFN signaling (Yokota et al., 2001). To see
if type II IFN-dependent Stat-1 phosphorylation was inhibited under
our infection conditions, we mock infected or infected Vero cells for
10 h and treated them with IFNα or IFNγ at 104 U/mL as indicated,
beforeWestern blot analysis with antibodies for pStat-1, Stat-1, ICP27,
and actin. Stat-1 was phosphorylated in mock-infected cells following
treatment with either type of IFN (Fig. 3, lanes 2 and 3). However, in
HSV-1 infected cells, Stat-1 was phosphorylated only after treatment
with IFNγ (Fig. 3, lane 6), not with IFNα (Fig. 3, lane 5). These results
argued that HSV-1 affects type I but not type II signaling. It is therefore
very likely that the inhibition occurs at or before Jak-1 activation.
HSV-1 infection inhibits IFNα-induced ISG15 expression in an
ICP27-independent manner
Other studies have shown that HSV-1 inhibited reporter gene
activity from constructs containing ISREs and GASs (Yokota et al.,
2001). However, there were no published reports of the effects of
ICP27 on the expression of endogenous ISG expression. We therefore
tested the capacity of HSV-1 to inhibit expression of the ISG15 protein,
a ubiquitin-like interferon-stimulated protein that gets conjugated to
other proteins with as yet undetermined consequences (Biron and
Sen, 2007; Zhao et al., 2004, 2005).
Wemock-infected or infected Vero cells withWT HSV-1 or ICP27−
virus at anMOI of 20 for 10 h and treatedwith IFNα 2 h before harvest,
as indicated (Fig. 4). Western blot analysis was performed with
antibodies speciﬁc for pStat-1, ISG15, and GAPDH. Phosphorylation of
Stat-1 and ISG15 expression were induced in mock-infected cells after
treatment with IFNα (Fig. 4, lane 2). Consistent with previous results,
cells infected with WT HSV-1, IFNα treatment showed reduced Stat-1
Fig. 5. Type I IFN receptor levels do not change over the course of infection. Vero cells
were mock infected (lanes 1–4) or infected (MOI=20) with WT HSV-1 (KOS, lanes 5–
8) for 2 h (odd lanes) or 10 h (even lanes) and treated with IFN for 30 min before
harvest (lanes 3–4, 7–8). Western blot analysis was done with antibodies speciﬁc for
IFNAR1, IFNAR2, and GAPDH.
Fig. 6. ICP27 does not affect the splicing or nuclear export of IFNAR2 transcripts. Vero
cells weremock-infected or infected (MOI=20)with wt HSV-1 (KOS, A: lane 2, B: lanes
3–4) or ICP27− virus (5dl1.2, A: lane 3, B: lanes 5–6) for 10 h. RNA was harvested from
whole cells (A) or cells fractionated into nuclear and cytoplasmic components (B) and
Northern blot analysis was done with probes speciﬁc for IFNAR2 and U3 snRNA.
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Surprisingly, though Stat-1 was phosphorylated after IFNα treatment
in cells infected with the ICP27− virus, ISG15 expression was not
induced (Fig. 4, lane 6). These data suggested that there are ICP27-
dependent and ICP27-independent mechanisms of inhibition of type I
IFN signaling.
HSV-1 infection does not alter levels of Interferon α/β receptor chain 1
or 2 (IFNAR1, 2)
Because HSV-1 infection inhibited type I, but not type II IFN
signaling, we reasoned that a signaling activity upstream of Jak-1 such
as the type I IFN receptor might be affected. Previous reports with vhs
mutant viruses showed that late in infection there was a slight
decrease in the protein levels for the IFNα/β receptor (Chee and
Roizman, 2004). However, we and others have observed an effect of
HSV-1 on IFN signaling at much earlier times post-infection than the
time when IFN receptor levels decreased (Johnson, Song, and Knipe,
2008; Yokota et al., 2001).
To determine if there was a decrease in IFNAR levels in our
infection conditions, Vero cells were mock-infected or infected with
WT HSV-1 (KOS) at an MOI of 20 for 2 or 10 h and treated with
interferon 30 min before harvest. Western blot analysis was done
with antibodies speciﬁc for IFNAR1, IFNAR2, and GAPDH. There were
no consistent changes in IFNAR1 or IFNAR2 levels, regardless of
infection or treatment with IFN (Fig. 5). These results suggested that
any degradation of IFNAR1 and IFNAR2 at later times post-infection is
not the major mechanism of the inhibition of type I IFN signaling.
HSV-1 infection does not cause differential splicing or nuclear export of
IFNAR2 RNA
We showed above that ICP27 is sufﬁcient to cause release of a
soluble heat-stable peptide that inhibits type I IFN signaling. Because
ICP27 has been implicated in RNA processing and nuclear export
(Hardwicke and Sandri-Goldin, 1994; Hardy and Sandri-Goldin, 1994;
Pearson, Knipe, and Coen, 2004; Phelan et al., 1993; Sandri-Goldin and
Hibbard, 1996; Sciabica, Dai, and Sandri-Goldin, 2003; Wadd et al.,
1999) and has been shown to stabilize IFNβ RNA (Mosca, Pitha, and
Hayward, 1992), we hypothesized that ICP27 might affect splicing of
the transcript from the IFNAR2 gene. ThemRNA for IFNAR2, the major
IFN-binding subunit of the receptor (Novick, Cohen, and Rubinstein,
1994), has a splicing variant that encodes a 27 kDa secreted form of
the receptor (Hardy et al., 2001; Lutfalla et al., 1995; Novick, Cohen,
and Rubinstein, 1994). This secreted IFNAR2 has been shown to
inhibit type I IFN signaling in cells that express full-length IFNAR2(Hardy et al., 2001). Therefore, ICP27might be affecting the splicing or
nuclear export of IFNAR2 RNAs and causing preferential expression of
the secreted IFNAR2 protein.
To determine if ICP27 was affecting the splicing of IFNAR2 mRNAs,
we mock infected or infected Vero cells with WT or ICP27− HSV-1,
and at 10 h, we isolated RNA and subjected it to Northern blot analysis
with a hybridization probe speciﬁc for a region of the IFNAR2
transcript that is shared between splice variants (Fig. 6A). There was
no apparent difference in the ratio of IFNAR2 RNA splice variant levels
between mock, WT, and ICP27−-infected cells (Fig. 6A).
Although there was no difference in the whole cell IFNAR2 mRNA
levels, we hypothesized that ICP27 might be causing differential
nuclear export of the IFNAR2 mRNA splice variants. Vero cells were
mock-infected or infectedwithWT or ICP27−HSV-1 for 10 h, and RNA
was isolated from nuclear and cytoplasmic fractions. Northern blot
analysis was performed as above with probes speciﬁc for IFNAR2
mRNA and U3 snRNA, the latter as a control for our fractionation.
There was no apparent difference in relative nuclear to cytoplasmic
levels of the sIFNAR2 vs. IFNAR2 RNA species between mock, WT, or
ICP27−-infected cells (Fig. 6B). These results argued that the
mechanism by which ICP27 induces the secreted inhibitory factor
did not involve splicing or nuclear export of IFNAR2 mRNAs.
Discussion
Type I IFN is one of the ﬁrst lines of defense that a host mounts
against viral infection. As such, it is important for the ﬁtness of many
viruses that they evade the induction or the effects of type I IFN.
Several viruses do this by antagonizing either the activation or activity
of IRF-3 to prevent type I IFN expression (Ronco et al., 1998; Talon et
al., 2000). In contrast, other viruses inhibit the IFN signaling pathway
itself through interactions with and/or degradation of the Jak/Stat
factors (Basler et al., 2000; Gao et al., 1997). Thus far, the only virus
family found to encode a secreted type I IFN antagonist is Poxviridae.
Vaccinia, tanapox, and ectromelia viruses encode secreted IFNα/β
receptor homologs that inhibit IFN signaling.
HSV-1 encodes several IFN antagonists, including ICP0, which
inhibits IRF-3 nuclear accumulation (Melroe, DeLuca, and Knipe,
2004); ICP27, which inhibits IFNα-induced Stat-1 phosphorylation
and nuclear accumulation (Johnson, Song, and Knipe, 2008), and
γ34.5, which counteracts the activity of PKR (Chou et al., 1995; He,
Gross, and Roizman, 1997; Johnson, Song, and Knipe, 2008; Leib et al.,
2000), an ISG that phosphorylates the translation initiation factor
eIF2a to inhibit protein synthesis (He, Gross, and Roizman, 1998;
Samuel, 1979a,b).
26 K.E. Johnson, D.M. Knipe / Virology 396 (2010) 21–29HSV-1 infection or ICP27 expression causes the inhibition of type I IFN
signaling in surrounding cells
We observed that HSV-1 infection at a fairly low MOI causes
inhibition of Stat-1 nuclear accumulation in a larger percentage of
cells than are infected, as determined by ICP27 staining. We also show
that transfection of cells with a plasmid encoding ICP27 is sufﬁcient
for the inhibition of Stat-1 nuclear accumulation in a larger
percentage of cells than stain positive for ICP27. This indicates that
either ICP27 is present at levels below detection by immunoﬂuores-
cence in all cells in which we see no nuclear accumulation of Stat-1, or
that HSV-1 infection and ICP27 expression cause the secretion of an
inhibitory factor that affects the surrounding cells, possibly similar in
mechanism to the vaccinia virus B18R protein (Alcamí and Smith,
1995; Colamonici et al., 1995). This effect could have very important
implications for viral spread because HSV-1 replication is inhibited in
cells that have been pre-exposed to IFNα (Altinkilic and Brandner,
1988; Mittnacht et al., 1988).
ICP27 expression causes the release of a heat-stable, protease-sensitive
soluble IFNα antagonist
To differentiate between the two models described above, we
transferred medium from cells transfected with empty vector or an
ICP27 expression vector to naïve Vero cells. We found that medium
harvested from cells transfected with empty vector has no effect on
IFNα-induced nuclear accumulation of Stat-1. However, there is
inhibition of Stat-1 nuclear accumulation conferred by medium from
cells transfected with an ICP27 expression plasmid. We also found
that this inhibitory activity is heat-stable and protease sensitive. These
results suggested that there is a stable peptide secreted from ICP27-
expressing cells that affects the IFN signaling in surrounding cells.
These results also raise the possibility that the secreted factor is
either a cellular protein or all or part of ICP27. We were unable to
detect ICP27 in the overlaid cells by immunoﬂuorescence or in the
medium byWestern blot (data not shown). Because the commercially
available antibodies to ICP27 are all to N-terminal epitopes, however,
it is possible that there is a C-terminal cleavage product of ICP27 that
causes the inhibition.
HSV-1 infection inhibits type I but not type II IFN-dependent Stat-1
phosphorylation
Jak-1 and Stat-1 are involved in both type I and type II IFN
signaling. We and others have shown that HSV-1 inhibits IFNα-
induced Stat-1 phosphorylation (Chee and Roizman, 2004; Mittnacht
et al., 1988; Yokota et al., 2001). To determine if Stat-1 or Jak-1 were
speciﬁcally targeted by the virus, we tested the capacity of HSV-1 to
inhibit IFNγ-induced Stat-1 phosphorylation as well, and we found
that IFNγ-induced Stat-1 phosphorylation is not inhibited by HSV-1.
Because Jak-1 activation is necessary for Stat-1 phosphorylation
(Darnell, Kerr, and Stark, 1994; David et al., 1993; Johnson, Song, and
Knipe, 2008; Platanias, Uddin, and Colamonici, 1994) these results
suggested that the effect of HSV-1 was on a factor or signaling event
upstream of Jak-1 activation,. This could include an effect on IFNα,
itself, one or both of the receptor proteins, or the interactions between
the receptor and the janus kinases.
The lack of inhibition of IFNγ-induced Stat-1 phosphorylation
contrasts somewhat with previous studies that show a decrease in
IFNα-induced luciferase activity from an ISRE reporter construct and a
less pronounced decrease in IFNγ-induced luciferase from a GAS
reporter construct. However, we have also shown that though HSV-1
inhibition of IFNα-induced Stat-1 phosphorylation and nuclear
accumulation is ICP27-dependent, there is ICP27-independent inhi-
bition of IFNα-induced ISG15 expression. This suggested the
possibility of multiple levels of inhibition of the type I IFN signalingpathway. Another immediate early protein, ICP0 has been shown to
be important for the inhibition of expression of some ISGs, including
ISG54, ISG56, and ISG15 possibly through its activity as a ubiquitin
ligase (Eidson et al., 2002). It is also possible that HSV-1 encodes an
activity that inhibits the association of Stat-1 with DNA or with
important transcription co-factors, such as CBP/p300. This would
result in the inhibition of type I and type II IFN-induced gene
expression even if Stat-1 phosphorylation is not affected.
HSV-1 infection has no effect on the levels of the type I IFN
receptor subunits
Because of the implications that the step of IFNα signaling that is
affected by HSV-1 is upstream of Jak-1 activation, we looked at the
stability of the type I IFN receptor. In our hands, both IFNAR1 and
IFNAR2 levels are stable in cells up to 10 hpi. This argues that HSV-1 is
not causing the degradation of IFNAR in time to effect the inhibition
of IFNα-dependent Stat-1 phosphorylation. A previous study (Chee
and Roizman, 2004) showed a decrease in the levels of one of the
receptor proteins, beginning at 8 hpi; however, they infected HeLa
cells with HSV-1 strain F, whichmay cause more protein degradation
than the KOS strain. It is possible that HSV-1 strain KOS does cause
degradation of IFNAR at later times post-infection. However, it is also
possible that the decrease in IFNAR levels seen in that study is due
to normal degradation of the protein but decreased synthesis of
IFNAR due to the host protein synthesis shut-off functions of vhs and
ICP27.
Although the type I receptor levels appear constant through the
time post-infection that IFNα-induced Stat-1 phosphorylation is
inhibited, it is possible that the subcellular localization of the protein
is altered by HSV-1 infection. If, for example, one or both of the
receptor subunits were internalized during HSV-1 infection, there
would be decreased sensitivity of infected cells to IFNα treatment.
HSV-1 has previously been shown to cause internalization of the EGF
receptor via interactions between the HSV-1 protein ICP0 and the
cellular proteins CIN85 and Cbl (Liang, Kurakin, and Roizman, 2005).
HSV-1 does not affect the splicing or nuclear export of IFNAR2 mRNAs
ICP27 has several functions, including inhibition of splicing,
causing differential use of polyadenylation signals, and roles in RNA
export from the nucleus (Hann et al., 1998; Hardwicke and Sandri-
Goldin, 1994; Hardy and Sandri-Goldin, 1994; Koffa et al., 2001; Liang,
Kurakin, and Roizman, 2005; McGregor et al., 1996; McLauchlan et al.,
1992; McLauchlan, Simpson, and Clements, 1989; Phelan et al., 1993;
Sciabica, Dai, and Sandri-Goldin, 2003; Wadd et al., 1999). ICP27 has
recently also been shown to promote production of a secreted form of
the HSV-1 glycoprotein gC by causing the transmembrane domain
coding sequences to be spliced out of the mRNA (Sedlackova et al.,
2008).
The mRNA for IFNAR2 has four known splice variants encoding
three proteins with some shared domains (Lutfalla et al., 1995): the
full-length signaling molecule, a dominant-negative molecule con-
taining the IFN-binding extracellular and transmembrane domains
(deWeerd, Samarajiwa, and Hertzog, 2007; Gazziola et al., 2005), and
a secreted form with only the IFN-binding ectodomain, which has
been shown to inhibit signaling in cells with a full complement of
IFNAR2 (de Weerd, Samarajiwa, and Hertzog, 2007; Lutfalla et al.,
1995; Novick, Cohen, and Rubinstein, 1994). We hypothesized that
ICP27 might affect the splicing or nuclear export of the splice variants
of IFNAR2, favoring the expression of the secreted form of the
receptor. However, we found no differences in the ratios of secreted
IFNAR2 RNA to full-length IFNAR2 RNA between mock-, WT-, and
ICP27−-infected cells. We were also unable to ﬁnd sIFNAR2 by
Western blot in the medium from cells transfected with an ICP27
expression vector (data not shown). These results are certainly
27K.E. Johnson, D.M. Knipe / Virology 396 (2010) 21–29suggestive that sIFNAR2 is not the secreted factor induced by ICP27
expression that inhibits Stat-1 nuclear accumulation in response to
IFNα. However, it is possible that ICP27 causes increased secretion of
sIFNAR2 from cells. It is also possible that ICP27 expression causes the
expression and secretion of a dominant negative IFN from cells.
These results have very important implications for HSV-1 spread
and evasion of innate immunodetection because HSV-1 replication is
inhibited in cells that have been exposed to IFN before infection
(Hardy et al., 2001; Mittnacht et al., 1988; Oberman and Panet, 1988).
This inhibition makes it very difﬁcult for the virus to replicate
efﬁciently, infect new cells, and establish latency in the host. By
causing the secretion of a factor that inhibits IFNα signaling in
neighboring, uninfected cells, HSV-1maintains a cellular environment
conducive to its own replication and spread. The inhibition of the
signaling pathway upstream of Jak-1 activation may be due to the
secreted protein competing for binding between IFNα and IFNAR2.
This would be consistent with our data showing no difference in
IFNAR levels after 10 h of infection and the inhibition of type I but not
type II IFN-induced Stat-1 phosphorylation.
Materials and methods
Cells and viruses
Vero cells weremaintained in Dulbecco's modiﬁed Eagle's medium
(DMEM, Gibco-BRL) supplemented with 5% heat-inactivated fetal calf
serum (FCS) and 5% heat-inactivated newborn calf serum (BCS).
Viral stocks were grown in the appropriate complementing cell
lines (the HSV-1 WT KOS was grown on Vero cells and 5dl1.2
(McCarthy, McMahan, and Schaffer, 1989) was grown on V827 cells.
Viral titers were determined by plaque assay in Vero cells or the
indicated complementing cell line as described (Knipe and Spang,
1982). For infection experiments, viruses were used at an MOI of 1 or
20 to infect Vero cells, which were incubated at 37°C in PBS with 1%
BCS, 0.1% glucose for 1 h before removal of the inoculum and addition
of DMEM supplemented with 1% FCS.
Western blots
Mock-infected or infected cells were harvested from 25-cm2 ﬂasks
in 400 μL of SDS sample buffer (62.5mMTris–HCl pH 6.8, 20% glycerol,
2% SDS, 0.1% bromophenol blue, 10 mM β-glycerophosphate, 5 mM
sodium ﬂuoride, 1 mM sodium vanadate, 0.5% β-mercaptoethanol)
and resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis in 12% bis-crosslinked polyacrylamide gels and electrically
transferred to nitrocellulose in transfer buffer (25 mM Tris, 192 mM
Glycine, 20% methanol) overnight at 4 °C with the Bio-Rad Transblot
system. Membranes were probed with antibodies to Stat-1 (1:1000),
pStat-1 (1:500), actin (1:1000), IFNAR1 (1:750), or IFNAR2 (1:500)
from Santa Cruz Biotechnology, Inc., ICP27 (H1119 at 1:10,000) from
Virusys, and GAPDH (1:40,000) from Abcam, in PBST (0.5% Tween 20
in PBS from Gibco), washed twice for 5 min in PBST, and incubated
with secondary antibodies conjugated to horseradish peroxidase
(HRP) diluted 1:5000–1:20,000 from Santa Cruz Biotechnology, Inc.
HRP activity was detected using Western Lightening chemilumines-
cence reagent (PerkinElmer) or Lumilight Western blotting substrate
(Roche) and exposed on X-ray ﬁlm (Kodak).
Plasmids and transfections
Plasmid pCI was obtained from Promega. Plasmid pCI-ICP27 has
been described previously (Olesky et al., 2005). At 24 h before
transfection, Vero cells were seeded into six-well plates containing
glass coverslips for ﬂuorescence experiments. Transfections were
carried out using Opti-MEM medium (Gibco) and Genejuice reagent
(Novagen) according to the manufacturer's instructions.Immunoﬂuorescence
Vero cells were seeded for immunoﬂuorescence at 5×105 cells/
well on glass coverslips in six-well plates and incubated overnight at
37°C before infection or transfection, after which they were treated as
indicated with IFNα (PBL biomedical laboratories). Following incu-
bation for the appropriate time, cells were ﬁxed in 3.7% formaldehyde
in phosphate-buffered saline (PBS) for 10 min at room temperature,
and cells were permeabilized by incubation in methanol at−20°C for
2 min. Following several washes in PBS, cells were incubated
overnight in IF buffer (PBS containing 2.5% goat serum [Sigma]).
Dylight-488 conjugated streptavidin (Pierce) or primary antibodies
were diluted appropriately (Streptavidin-488 1:50, STAT-1 1:50) and
applied to cells in PBS, and the cells were incubated for 45 min at
37 °C. Cells were washed twice for 5 min in PBS. Secondary antibodies
conjugated to Alexa 594 and Alexa 488 dyes were obtained from
Molecular Probes, Inc., andwere applied at 1:1000 in PBS for 30min at
37 °C. Cells were then washed twice for 10 min in PBS at room
temperature, and coverslips were mounted with Prolong antifade
reagent (Molecular Probes, Inc.).
For cell culture medium transfer experiments, medium was
removed from transfected Vero cells at 24 h post-transfection, treated
as indicated by heating to 55 °C for 60min and then to 95 °C for 10min
in the presence or absence of 100μg/mL proteinase K (Roche), and
cooled to 37 °C or spun through 10 or 50 kDa molecular weight cut off
Microcon® ﬁlters (Millipore) according to the manufacturer's
instructions before overlaying new Vero cells on coverslips.
Slides were viewed with an Axioplan 2 microscope (Zeiss) with a
63×objective and a 10×ocular objective. Images were collected with
the Axiovision 4.5 suite of programs (Zeiss) and a Hamamatsu C4742-
95-12NR digital camera.
RNA isolation and Northern blot analysis
Total RNAwas isolated from Vero cells using TRI reagent (Ambion)
according to the manufacturer's instructions. To separate RNA into
nuclear and cytoplasmic fractions, cells were lysed by incubation for
5min on ice in lysis buffer (50mMTris–Cl, pH8.0, 100mMNaCl, 5mM
MgCl2, 0.5% v/v Nonidet P-40, ﬁlter sterilized) and nuclei were
removed by centrifugation. RNA was isolated from nuclei using TRI
reagent, according to the manufacturer's instructions. RNA was
isolated from the cytoplasm by adding SDS to 0.05% and extracting
twice with phenol/chloroform/isoamyl alcohol and once with
chloroform/isoamyl alcohol. Cytoplasmic RNA was ethanol precipi-
tated and resuspended in H2O.
For Northern blots, 5μg of RNA of each sample was resolved in an
agarose gel using the NorthenMax-Gly™ kit (Ambion) and transferred
to BrightStar® Plus positively charged nylon membrane (Ambion)
according to the manufacturer's instructions. DNA probes for IFNAR2
(5′-GCTCATCACTGTGCTCTAAATAAACAGATACACA GTAGTTCGTGTTT
GGAA-3′) and U3 (5′-ACCACTCAGACCGCGTTCTCTCCCT CTCACTCCC-
CAATACGGAGAGAAGAACGA-3′) were obtained from IDT and bioti-
nylated using Brightstar® Psoralen-biotin nonisotopic labeling kit
(Ambion) according to the manufacturer's instructions. Probes were
hybridized using UltraHyb® hybridization buffer (Ambion) and blots
were washed and RNA detected using the BrightStar® biodetect kit
(Ambion) according to the manufacturer's instructions.References
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